https://www.medicinesdevelopment.com https://www.medicinesdevelopment.com/about https://www.medicinesdevelopment.com/contact/careers https://www.medicinesdevelopment.com/contact https://www.medicinesdevelopment.com/our-work/medicines https://www.medicinesdevelopment.com/news https://www.medicinesdevelopment.com/our-work https://www.medicinesdevelopment.com/our-work/pipeline https://www.medicinesdevelopment.com/policies https://www.medicinesdevelopment.com/resources https://www.medicinesdevelopment.com/about/team https://www.medicinesdevelopment.com/timeline https://www.medicinesdevelopment.com/search https://www.medicinesdevelopment.com/uk https://www.medicinesdevelopment.com/donate https://www.medicinesdevelopment.com/support-us https://www.medicinesdevelopment.com/our-work/pilot-field-project https://www.medicinesdevelopment.com/coming-soon https://www.medicinesdevelopment.com/newsletter https://www.medicinesdevelopment.com/news/1-3-million-boost-to-develop-victorias-biotech-skills https://www.medicinesdevelopment.com/news/2021-annual-report-published https://www.medicinesdevelopment.com/news/2022-and-2023-annual-report https://www.medicinesdevelopment.com/news/2023-24-annual-report https://www.medicinesdevelopment.com/news/2023-international-conference-on-public-health-in-africa https://www.medicinesdevelopment.com/news/abcs-health-report-covers-moxidectin-approval https://www.medicinesdevelopment.com/news/addressing-scabies-the-neglected-of-neglected-disease https://www.medicinesdevelopment.com/news/american-society-for-tropical-medicine-and-hygiene-annual-meeting https://www.medicinesdevelopment.com/news/american-society-of-tropical-medicine-and-hygiene-annual-meeting https://www.medicinesdevelopment.com/news/american-society-of-tropical-medicine-and-hygiene-annual-meeting-2 https://www.medicinesdevelopment.com/news/an-update-on-the-progress-of-our-major-programs https://www.medicinesdevelopment.com/news/australian-government-funding https://www.medicinesdevelopment.com/news/excellence-in-innovation-award https://www.medicinesdevelopment.com/news/fast-company-magazine-has-named-mdgh-founder-mark-sullivan-to-its-2019-list-of-100-most-creative-people-in-business https://www.medicinesdevelopment.com/news/for-moxidectin-fda-approval-for-river-blindness-was-just-the-beginning https://www.medicinesdevelopment.com/news/ghana-becomes-first-river-blindness-endemic-country-to-approve-moxidectin https://www.medicinesdevelopment.com/news/ghanaian-onchocerciasis-expert-committee-meeting https://www.medicinesdevelopment.com/news/good-management-practice-partners-address-project-management-challenges-for-neglected-tropical-disease-study https://www.medicinesdevelopment.com/news/human-neonatal-rotavirus-vaccine-paper-in-nejm https://www.medicinesdevelopment.com/news/immusant-nexpep-present-results-of-phase-1-coeliac-vaccine https://www.medicinesdevelopment.com/news/important-cautionary-statement-regarding-in-vitro-study-of-ivermectin-and-sars-cov-2 https://www.medicinesdevelopment.com/news/improvements-to-the-us-fda-priority-review-program-for-neglected-diseases https://www.medicinesdevelopment.com/news/mark-sullivan-awarded-officer-of-the-order-of-australia https://www.medicinesdevelopment.com/news/mark-sullivan-invited-to-attend-northern-australia-investment-forum https://www.medicinesdevelopment.com/news/mark-sullivan-joins-the-investment-committee-of-auckland-uniservices https://www.medicinesdevelopment.com/news/mark-sullivan-one-of-eys-social-entrepreneurs-of-the-year https://www.medicinesdevelopment.com/news/mark-sullivan-presenting-at-american-society-of-tropical-medicine-and-hygiene-14-november-2016-atlanta-ga https://www.medicinesdevelopment.com/news/mark-sullivan-speaking-at-priority-review-voucher-summit-2-3-november-2016-arlington-va https://www.medicinesdevelopment.com/news/mass-drug-administration-for-scabies-control https://www.medicinesdevelopment.com/news/mdgh-announces-in-licensing-of-investigational-treatment-for-tb-and-leprosy-from-amgen https://www.medicinesdevelopment.com/news/mdgh-awarded-2018-ausbiotech-and-j-j-innovation-industry-excellence-award https://www.medicinesdevelopment.com/news/mdgh-discloses-novo-nordisk-as-purchaser-of-its-prv https://www.medicinesdevelopment.com/news/mdgh-founder-named-2019-victorian-australian-of-the-year https://www.medicinesdevelopment.com/news/mdgh-has-been-named-as-one-of-fast-companys-worlds-most-innovative-companies-for-2019-ranked-7th-most-innovative-not-for-profit-company https://www.medicinesdevelopment.com/news/mdgh-is-an-official-partner-for-world-ntd-day https://www.medicinesdevelopment.com/news/mdgh-is-proud-to-be-a-foundation-member-of-the-global-health-alliance-melbourne https://www.medicinesdevelopment.com/news/mdgh-joins-neglected-tropical-disease-ngo-network https://www.medicinesdevelopment.com/news/mdgh-opens-its-phase-2-clinical-trial-of-dovramilast-in-people-with-leprosy-type-2-reaction https://www.medicinesdevelopment.com/news/mdgh-representation-at-the-international-congress-for-tropical-medicine-and-malaria-18-22-november-2016 https://www.medicinesdevelopment.com/news/mdgh-submits-an-investigational-new-drug-application-for-dovramilast-in-the-treatment-of-leprosy-type-2-reaction https://www.medicinesdevelopment.com/news/mdgh-update-december-2021 https://www.medicinesdevelopment.com/news/mdgh-update-june-2021 https://www.medicinesdevelopment.com/news/mdgh-update-june-2022 https://www.medicinesdevelopment.com/news/mdgh-update-march-2021 https://www.medicinesdevelopment.com/news/mdgh-update-march-2022 https://www.medicinesdevelopment.com/news/mdgh-update-october-2022 https://www.medicinesdevelopment.com/news/medicines-development-appoints-first-development-manager-for-training-program https://www.medicinesdevelopment.com/news/medicines-development-at-ausbiotech-2010 https://www.medicinesdevelopment.com/news/medicines-development-awarded-1-3-million-grant-from-victorian-government-to-develop-vital-skills-for-local-biotech-industry https://www.medicinesdevelopment.com/news/medicines-development-director-mark-sullivan-joins-victorian-premier-hon-ted-baillieu-on-super-trade-mission-to-india https://www.medicinesdevelopment.com/news/medicines-development-employee-joins-the-rv3-rotavirus-vaccine-team-at-mcri https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-announces-inclusion-of-moxidectin-on-world-health-organization-essential-medicines-lists https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-announces-new-head-of-philanthropy https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-announces-submission-of-the-moxidectin-nda-to-the-fda-and-priority-review-designation https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-atticus-medical-enroll-first-patient-in-phase-2b-study-of-moxidectin-in-scabies https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-is-a-founding-member-of-the-clinical-trials-community-africa-network https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-is-a-signatory-of-the-nagasaki-statement https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-joins-the-whos-global-accelerator-for-paediatric-formulations-gap-f-network https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-opens-a-new-study-site-in-cote-divoire https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-receives-fda-orphan-drug-designation-for-dovramilast-to-treat-leprosy-type-2-reaction https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-receives-u-s-fda-clearance-of-investigational-new-drug-application-for-dovramilast-in-leprosy-type-2-reaction https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-receives-us-1m-grant-for-moxidectin-programs https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-receives-us-4-9m-grant-for-moxidectin-programs https://www.medicinesdevelopment.com/news/medicines-development-for-global-health-signs-the-kigali-declaration https://www.medicinesdevelopment.com/news/medicines-development-is-now-an-approved-supplier-for-the-small-technology-industry-uptake-program https://www.medicinesdevelopment.com/news/medicines-development-places-development-manager-at-hatchtech https://www.medicinesdevelopment.com/news/medicines-development-places-development-manager-at-immuron https://www.medicinesdevelopment.com/news/medicines-development-places-first-development-manager-at-virax-holdings-ltd https://www.medicinesdevelopment.com/news/medicines-development-retains-the-services-of-d3-medicine https://www.medicinesdevelopment.com/news/medicines-development-sets-its-sights-on-a-prv https://www.medicinesdevelopment.com/news/medicines-development-to-provide-development-support-to-consortium-of-australian-and-new-zealand-research-teams-following-6-8-million-wellcome-trust-uk-seeding-drug-discovery-award https://www.medicinesdevelopment.com/news/medicines-developments-collaborator-dr-bruce-d-walker-director-of-the-ragon-institute-of-mgh-mit-and-harvard-features-in-nature https://www.medicinesdevelopment.com/news/momentum https://www.medicinesdevelopment.com/news/monash-university-and-medicines-development-team-up-to-tackle-gut-infections https://www.medicinesdevelopment.com/news/moxidectin-as-a-new-oral-treatment-for-human-scabies https://www.medicinesdevelopment.com/news/moxidectin-for-river-blindness-clinical-study-updates https://www.medicinesdevelopment.com/news/moxidectin-for-scabies-clinical-study-updates https://www.medicinesdevelopment.com/news/moxidectin-nominated-for-best-pharmaceutical-product-in-2019-prix-galien-usa-awards https://www.medicinesdevelopment.com/news/moxidectin-phase-iii-study-lancet-publication https://www.medicinesdevelopment.com/news/new-funding-for-continued-development-of-onchocerciasis-treatment-moxidectin https://www.medicinesdevelopment.com/news/new-modelling-study-suggests-potential-for-moxidectin-to-accelerate-elimination-of-river-blindness-in-africa https://www.medicinesdevelopment.com/news/nobel-prize-for-medicine-recognises-anti-parasite-drug-discoveries https://www.medicinesdevelopment.com/news/opportunties-and-challenges-associated-with-tackling-metastasis https://www.medicinesdevelopment.com/news/phase-3b-4-study-comparing-moxidectin-with-ivermectin-in-river-blindness-is-fully-enrolled https://www.medicinesdevelopment.com/news/podcast-interview-with-mark-sullivan https://www.medicinesdevelopment.com/news/powering-up-the-people-pipeline https://www.medicinesdevelopment.com/news/priority-review-voucher-news https://www.medicinesdevelopment.com/news/reaching-the-last-mile-forum-dubai-uae https://www.medicinesdevelopment.com/news/recent-prv-article-from-harvard-researchers https://www.medicinesdevelopment.com/news/record-amount-for-latest-prv-sale https://www.medicinesdevelopment.com/news/recruitment-into-phase-2b-clinical-trial-for-scabies-complete https://www.medicinesdevelopment.com/news/rotavirus-vaccine-proven-to-be-effective-in-clinical-trials https://www.medicinesdevelopment.com/news/safety-and-immunogenicity-of-a-neonatal-rotavirus-vaccine-in-a-phase-2a-study https://www.medicinesdevelopment.com/news/scabies-program-update https://www.medicinesdevelopment.com/news/spotlight-on-dr-peya-gaye-senior-clinical-project-manager-medicines-development-for-global-health https://www.medicinesdevelopment.com/news/sublingual-interferon-alpha-project-wins-nhmrc-funding https://www.medicinesdevelopment.com/news/tga-approves-registration-of-ivermectin https://www.medicinesdevelopment.com/news/the-effect-of-scabies-is-more-than-itching https://www.medicinesdevelopment.com/news/the-global-health-investment-fund-and-medicines-development-for-global-health-nannounce-the-sale-of-priority-review-voucher https://www.medicinesdevelopment.com/news/the-push-to-approve-scabies-treatment-in-australia https://www.medicinesdevelopment.com/news/therapeutic-vaccine-trials-to-start-in-london-uk https://www.medicinesdevelopment.com/news/u-s-fda-approves-moxidectin-for-the-treatment-of-river-blindness https://www.medicinesdevelopment.com/news/u-s-fda-expands-indication-for-moxidectin-to-treat-river-blindness-in-patients-as-young-as-four https://www.medicinesdevelopment.com/news/uk-and-us-offices-receive-charity-status https://www.medicinesdevelopment.com/news/update-september-2021 https://www.medicinesdevelopment.com/news/us-10-million-investment-into-the-registration-of-moxidectin-an-important-new-global-health-medicine-for-river-blindness https://www.medicinesdevelopment.com/news/welcome-to-the-newest-members-of-the-team https://www.medicinesdevelopment.com/news/whats-in-a-debossed-code https://www.medicinesdevelopment.com/diseases/leprosy https://www.medicinesdevelopment.com/diseases/lymphatic-filariasis https://www.medicinesdevelopment.com/diseases/river-blindness https://www.medicinesdevelopment.com/diseases/scabies https://www.medicinesdevelopment.com/diseases/soil-transmitted-helminth-infections https://www.medicinesdevelopment.com/diseases/strongyloidiasis https://www.medicinesdevelopment.com/diseases/tuberculosis https://www.medicinesdevelopment.com/resources/2021-annual-report https://www.medicinesdevelopment.com/resources/2022-2023-annual-report https://www.medicinesdevelopment.com/resources/2024-annual-report https://www.medicinesdevelopment.com/resources/2025-audited-financial-report https://www.medicinesdevelopment.com/resources/annual-report https://www.medicinesdevelopment.com/resources/dovramilast-for-leprosy-type-2-reaction https://www.medicinesdevelopment.com/resources/gone-webinar-moxidectin-development-update-20-august-2024 https://www.medicinesdevelopment.com/resources/identification-of-a-moxidectin-dose-for-4--to-11-year-old-children-to-support-registration-and-potential-use-for-onchocerciasis-elimination https://www.medicinesdevelopment.com/resources/modelling https://www.medicinesdevelopment.com/resources/momentum-project-brochure https://www.medicinesdevelopment.com/resources/moxidectin-for-lf https://www.medicinesdevelopment.com/resources/moxidectin-for-onchocerciasis-faqs https://www.medicinesdevelopment.com/resources/moxidectin-for-river-blindness-onchocerciasis-infographic https://www.medicinesdevelopment.com/resources/moxidectin-for-scabies https://www.medicinesdevelopment.com/resources/moxidectin-in-onchocerciasis-ongoing-clinical-trial-protocols-1 https://www.medicinesdevelopment.com/resources/moxidectin-in-onchocerciasis-ongoing-clinical-trial-protocols-2 https://www.medicinesdevelopment.com/resources/moxidectin-in-onchocerciasis-ongoing-clinical-trial-protocols-3 https://www.medicinesdevelopment.com/resources/newsletter-volume-10 https://www.medicinesdevelopment.com/resources/newsletter-volume-2 https://www.medicinesdevelopment.com/resources/newsletter-volume-3 https://www.medicinesdevelopment.com/resources/newsletter-volume-4 https://www.medicinesdevelopment.com/resources/newsletter-volume-5 https://www.medicinesdevelopment.com/resources/newsletter-volume-6 https://www.medicinesdevelopment.com/resources/newsletter-volume-7 https://www.medicinesdevelopment.com/resources/newsletter-volume-8 https://www.medicinesdevelopment.com/resources/newsletter-volume-9 https://www.medicinesdevelopment.com/resources/onchocerciasis-review-1 https://www.medicinesdevelopment.com/resources/onchocerciasis-review-2 https://www.medicinesdevelopment.com/resources/onchocerciasis-review-3 https://www.medicinesdevelopment.com/resources/one-pager-in-the-mayfair-times https://www.medicinesdevelopment.com/resources/phase-1-clinical-trials-moxidectin-1 https://www.medicinesdevelopment.com/resources/phase-1-clinical-trials-moxidectin-2 https://www.medicinesdevelopment.com/resources/phase-1-clinical-trials-moxidectin-3 https://www.medicinesdevelopment.com/resources/phase-2-clinical-trials-moxidectin-for-onchocerciasis https://www.medicinesdevelopment.com/resources/phase-3-clinical-trials-moxidectin-for-onchocerciasis https://www.medicinesdevelopment.com/resources/podcast-pharma-for-good-inside-medicines-development-for-global-health https://www.medicinesdevelopment.com/resources/the-emj-podcast-episode-160 https://www.medicinesdevelopment.com/documents/2021-financial-report https://www.medicinesdevelopment.com/documents/2022-financial-report https://www.medicinesdevelopment.com/documents/anti-corruption-and-anti-fraud https://www.medicinesdevelopment.com/documents/anti-corruption-and-anti-fraud-policy-external https://www.medicinesdevelopment.com/documents/child-protection-policy https://www.medicinesdevelopment.com/documents/child-protection-policy-2 https://www.medicinesdevelopment.com/documents/complaint-and-dispute-resolution https://www.medicinesdevelopment.com/documents/discrimination-harassment-vilification-and-bullying https://www.medicinesdevelopment.com/documents/environmental-social-and-health-and-safety-policy https://www.medicinesdevelopment.com/documents/financial-doc-1 https://www.medicinesdevelopment.com/documents/financial-doc-2 https://www.medicinesdevelopment.com/documents/financial-doc-3 https://www.medicinesdevelopment.com/documents/financial-doc-4 https://www.medicinesdevelopment.com/documents/financial-doc-5 https://www.medicinesdevelopment.com/documents/financial-policy-manual https://www.medicinesdevelopment.com/documents/gender-equality-disability-and-social-inclusion-policy https://www.medicinesdevelopment.com/documents/gender-equality-plan https://www.medicinesdevelopment.com/documents/hr-doc-1 https://www.medicinesdevelopment.com/documents/hr-doc-2 https://www.medicinesdevelopment.com/documents/hr-doc-3 https://www.medicinesdevelopment.com/documents/hr-doc-4 https://www.medicinesdevelopment.com/documents/hr-doc-5 https://www.medicinesdevelopment.com/documents/hr-document-6 https://www.medicinesdevelopment.com/documents/human-resources-manual https://www.medicinesdevelopment.com/documents/hybrid-working-policy https://www.medicinesdevelopment.com/documents/new-contractor-policy https://www.medicinesdevelopment.com/documents/policies-anti-corruption-and-anti-fraud-policy https://www.medicinesdevelopment.com/documents/policies-child-protection-policy https://www.medicinesdevelopment.com/documents/policies-privacy-policy https://www.medicinesdevelopment.com/documents/policies-whistleblower-policy https://www.medicinesdevelopment.com/documents/preventing-sexual-exploitation-abuse-harassment https://www.medicinesdevelopment.com/documents/privacy-policy-internal https://www.medicinesdevelopment.com/documents/risk-management-plan https://www.medicinesdevelopment.com/documents/risk-management-policy-and-risk-appetite-statement https://www.medicinesdevelopment.com/documents/sop-012-pharmacovigilance https://www.medicinesdevelopment.com/documents/sop-7-research-misconduct https://www.medicinesdevelopment.com/documents/sop-quality-risk-management https://www.medicinesdevelopment.com/documents/whistleblower-policy https://www.medicinesdevelopment.com/documents/whistleblower-policy-amgen https://www.medicinesdevelopment.com/documents/whistleblower-policy-ghif https://www.medicinesdevelopment.com/documents/working-practice-purchase-order-and-invoice-payment https://www.medicinesdevelopment.com/documents/wp-007-project-management-in-drug-development https://www.medicinesdevelopment.com/docs/dfat-pdap-2023 https://www.medicinesdevelopment.com/docs/financial-docs https://www.medicinesdevelopment.com/docs/hr-docs1